Navigation Links
Women Get Short Shrift in Many Heart Device Studies, Despite Requirement
Date:3/1/2011

DALLAS, March 1, 2011 /PRNewswire-USNewswire/ -- Despite a long-standing requirement for medical device makers to include women in studies they submit to the Food and Drug Administration for device approval, only a few include enough women or analyze how the devices work specifically in women, according to research reported in Circulation: Cardiovascular Quality and Outcomes.

(Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO)

"Women and men differ in their size, bleeding tendencies, and other factors that are directly relevant to how the devices will work," said Rita F. Redberg, M.D., M.Sc., senior author of the study and professor of medicine and director of Women's Cardiovascular Services at the University of California, San Francisco.

"It is likely that the benefits and risks of devices are different in women. Despite the directive to find out, it isn't happening."

In 1994, the Center for Devices and Radiological Health instituted a policy that all FDA submissions seeking new device approval must contain:

  • A gender-bias statement explaining whether the proportion of men and women in the study reflects the proportion of men and women who have the condition being treated.
  • Differences in the safety and effectiveness of the device in women.

  • In their analysis, researchers reviewed 123 studies contained in the pre-market approval applications for 78 high-risk cardiovascular devices (the category that includes heart valves and implanted defibrillators) that gained FDA approval between 2000 and 2007.

    In 28 percent of the studies, FDA summaries of the evidence didn't report the gender of study participants. In those that did, men made up an average of 67 percent.

    The investigators found that the required gender-bias statement was present in only 41 percent of the studies. Of studies that included the statement, 94 perce
    '/>"/>

    SOURCE American Heart Association
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
    2. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
    3. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    4. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
    5. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    6. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    7. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
    8. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
    9. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
    10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
    11. Bay Area Women Sought for Egg Freezing Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
    (Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
    ... Corporation (NASDAQ: HSKA ), a provider of ... today announced that Robert Grieve, Heska,s Chairman and CEO, will ... (PT), on March 14, 2012, Salon 1, Burgandy Track.  The ... Carlton, 1 Ritz Carlton Drive, Dana Point, California.  Dr. Grieve ...
    ... BETHESDA, Md., Feb. 23, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) ... clinical trial sites open and recruiting across the United ... DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most ... milestone ahead of schedule, as the Company had projected ...
    Cached Medicine Technology:Heska to Present at the 24th Annual ROTH Conference 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 3
    (Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
    (Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
    (Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
    (Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
    (Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
    Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
    ... Weight loss improves the sexual health of obese men with ... placed 31 obese men with type 2 diabetes on either ... diet meant to decrease calorie intake by 600 calories a ... to an easing of erectile dysfunction and improved sexual desire ...
    ... People living in a region of the southeastern United States ... higher rates of stroke deaths than the rest of the ... risk for sepsis, a severe illness in which bacteria overwhelms ... sepsis across the United States," said Dr. Henry Wang, associate ...
    ... University of Massachusetts Medical School have uncovered a novel ... immune response for malaria. Activation of this pathway appears ... by the immune system that may contribute to inflammation ... part in susceptibility for the most common and lethal ...
    ... , THURSDAY, Aug. 4 (HealthDay News) -- A ... comfortable using the clot-busting drug tissue plasminogen activator (tPA) to ... finds. An ischemic stroke is caused by blocked blood ... of neurology residents who say they,re comfortable using tPA rose ...
    ... have completed a comprehensive map of genetic mutations occurring ... The findings, reported in the Aug. 4 issue ... biological cause of the tumors, they say. To ... seven oligodendroglioma tissue samples, and focused attention on recurring ...
    ... the United States spend nearly four times as much dealing ... Most of the difference stems from the fact that Canadian ... multiple payers in the United States. These findings are ... -- the result of a research collaboration among Weill Cornell ...
    Cached Medicine News:Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 3Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3
    Cholesterol/HDL with 200 tests....
    Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
    ... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
    ... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
    Medicine Products: